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Abstract
The UK has a strong tradition of innovative evaluative health care research. There are, however,
considerable forces impeding collaboration between clinicians, academics, patients and their
advocates and industry. This paper argues that, if the UK is to regain a position at the forefront of
clinical research into evaluation of care, some of these forces need to be overcome. Now, with
explicit encouragement from funders within the UK's NHS, it is urgent that all parties discover
better ways of working together so that more broad and meaningful research can be produced in
a timely fashion.
Introduction
The National Health Service and the Welfare State have
come to be used as interchangeable terms, and in the
mouths of some people as terms of reproach. Why this is
so it is not difficult to understand, if you view everything
from the angle of a strictly individualistic competitive
society. A free health service is pure Socialism and as such
it is opposed to the hedonism of capitalist society. - Aneu-
rin Bevan, In Place of Fear[1].
I have never known much good done by those who
affected to trade for the public good. It is an affectation,
indeed, not very common among merchants, and very few
words need be employed in dissuading them from it. -
Adam Smith, Glasgow Edition of Smith's works[2].
The authors are friends and colleagues who have worked
together for years. Although career paths have been differ-
ent we do not feel that these should be divergent. For that
not to be the case, however, ways of working of all those
concerned do need to change and mature. The timing for
this is right with recent NHS initiatives. There are now
explicit directives for relevant research within the NHS to
be undertaken in close collaboration with industry,
academia and consumers[3]. UK Clinical Research Col-
laboration (UKCRC), for example, is a partnership of
organizations, including industry and consumers, focused
on production of high-quality clinical research within the
NHS. Although there are a number of shining examples of
the success of collaboration, it is, in many circumstances,
a problematic evolution fraught with misunderstandings
and frustrations[4]. Clinicians may see research as often
an academic or industrial exercise with little implication
for practice in the real world. For some areas of health care
this is, in no small measure, true. Industry may see the
NHS as an inefficient leviathan[5] with many committed
individuals but, as a whole, difficult to influence or bring
to industry standard. Academia may understand some of
the frustrations of research within the NHS but be, under-
standably, wary of becoming tainted with the reputation
that goes along with accepting industry support. After all,
in many instances, industry funding predicts results and,
in any case, there is a well-recognized risk of debauchery
associated with academics who work closely with indus-
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try[6,7]. In the face of the unresolved issues it has been
easy for academics to retreat into ivory towers untainted
by industry and untroubled by the needs of services.
Finally consumers can find it difficult to have as strong
and united a voice as that of health care professionals,
industry or academics and can end up feeling disempow-
ered and patronised.
These seemly different perspectives can lead to an uncom-
fortable low level of productivity in which sleaze, bias and
inefficiency are common. Everyone loses. Industry
becomes frustrated with the dearth of information forth-
coming from the NHS' important [and wealthy] popula-
tion and is more than tempted to go elsewhere to generate
similar data. Clinicians become passive and cynical recip-
ients of evidence generated from outside of the NHS. Aca-
demics are disempowered by living in ivory towers so far
from the real world. Patients and their carers miss the
opportunity to either become involved in studies or gain
benefits from truly relevant and local research, and the
NHS continues to struggle with avoidable inefficiencies.
Discussion
There are great gains of working together. It should be fea-
sible that the NHS remembers and respects the original
altruism upon which it was built and encourages the
opportunity of helping science move forward for the good
of those served by the NHS. It would seem feasible that
this also fits with the needs of industry, academia and
consumers. All stakeholders, however, may need to
change and to learn from the successes and failures of oth-
ers. The NHS is increasingly supporting research time of
its clinicians. This is still in the early stages but there is
active and practical encouragement (funding) of clini-
cians having protected research time[8]. There is concrete
recognition that research is part of an NHS job, is some-
thing to add variety to the clinical role, and is, potentially,
a healthy addition for the workforce[9]. The NHS has also
encouraged much clinically relevant research in swathes
of grant giving across all health care specialties. Depart-
ment of Health support is now even more explicitly for
the direct benefit of the National Health Service[10] but
also the genuine involvement [and not just consultation]
of people who use the service. The NHS is again in the
vanguard of encouraging real world, clinically meaningful
research.
Academia may still be some distance behind. Too much
work is still bid for or undertaken that can have little
direct or even indirect relevance to people within the
NHS[11]. There are still instances of an enormous cultural
barrier where it has not been understood that some of the
fine-grain issues that are of genuine interest to academia
may not be so valuable to providers of care. Although, of
course, there must be a balance struck between innova-
tive, imaginative research and the practical needs of the
NHS, there may still be many academics too far removed
from practical patient care. Nevertheless, there are signs
that academia, too, has responded to the NHS' encourage-
ment to climb down from the tower - the NHS' lead [and
money] has helped.
Industry, up to this point, has mostly worked with differ-
ent priorities[5]. Developing an innovative medicine,
preparation or device is a long-term and expensive enter-
prise. Most new medicines, for example, will fail on early
phase clinical studies, mainly because of safety reasons.
Others will not demonstrate clear cost benefits over exist-
ing treatments. When an innovative medicine reaches the
regulatory approval process, specific study features and
outcomes are demanded. Regulatory trials do not neces-
sarily hold a robust cost-effectiveness model from the per-
spective of NICE or the general public. The final and most
important customers in this complex chain are often
ignored in industry trials - patients and their carers.
Although industry has been knocking on the door of the
NHS for years, in many cases this resulted in a relation-
ship where the industry model of research has been
imposed on relatively few receptive researchers. As a
result, the examples of success are far fewer than would be
expected. It does help when the interests of all stakehold-
ers concur. Survival rates in people with cancer are of
interest to everyone. In other sub-specialties, where the
outcomes are not of equal interest to everyone, such as in
mental health, the results of co-working are much fewer,
less successful and less meaningful. When industry
respects the needs of the NHS, the NHS' capacity as one of
the largest single organisations providing health care, and
the sheer size of the NHS 'business' [eclipsing most com-
panies], then co-working has been proved to be fruit-
ful[12]. Where these elements are not considered, both
individuals and networks of individuals slip into an all
too familiar uneasy and often sleazy relationship betray-
ing principles upon the NHS was built.
Industry, academia, and even the NHS should learn from
patients and practitioners about clinically relevant patient
outcomes, and deliver solutions for their main unmet
health needs. The UK government's call for a collaborative
work between these providers might initially seem sim-
plistic, but, rather, is a unique opportunity to the NHS,
academia and industry to finally work for the people who
ultimately should to be beneficiaries of collaborative
research. The NHS has a fine tradition of imaginative clin-
ical research that, now, by some measures, has fallen far
behind some other countries in Europe. The Centre for
Medicines Research data suggests that the UK market
share of global patient recruitment fell from 6% in 2000
to around 2% in 2006 [13]. The same source also exam-
ined the number of patients in commercial trials and hasPublish with BioMed Central    and   every 
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found that the UK has declined from a third position in
2000 to ninth place in 2006. In terms of active sites, the
Average Relative Annual Growth Rate of countries of com-
mercial clinical trials showed the UK shrunk by 10%
between 2000 and 2006. In the same period, other Euro-
pean countries like Spain (14.9%) and Germany (11.7%)
achieved growth [14].
Conclusion
Recent initiatives within the NHS, imposing a cultural
change in academia and encouraging it in industry, make
this time an exciting opportunity for new research initia-
tives. Of course cultural change takes time, and individu-
als and networks will continue to produce yet more
studies of the type that have been seen for sixty years. In
some subspecialties we are barely at the stage of talks
about talks - but right across many health care specialties,
talks there are, both formal and informal[15]. Perhaps no
one will get all they want. Nevertheless, this initiative has
a chance of pushing the research culture in the UK
towards world-leading and ground breaking work again.
The initiatives are opening the doors to the NHS to pro-
vide a further service to patients and their carers via their
involvement in research, for academics to truly do imagi-
native and important work of clear relevance at the coal-
face of care, as well as for industry to clean up a tarnished
image and help gain practice-changing, evidence about
the interventions they have invested so much in.
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